Source Fact: IBK Investment & Securities / Published on June 29, 2026
Investment Opinion & Target Price: BUY (Maintain) / 2,090,000 KRW
Key Momentum: Strong core growth driven by global antibody therapeutics demand, alongside the imminent shift of delayed strike-related volumes into third-quarter revenues and the upcoming ramp-up of the Plant 5 expansion
📊 1. [Section Title: Valuation Indicators and Investment Metrics Analysis]
- Target Price & Investment Rating: Maintaining a BUY rating and a 12-month target price of 2,090,000 KRW for Samsung Biologics (207940). The stock presents a compelling entry window for valuation gap reduction following a period of underperformance relative to global peers like Lonza (+0.8%) and WuXi Biologics (+1.4%).
- Annual Earnings Forecast (2026F): Consolidated annual revenue is projected to grow by 20.1% year-over-year to 5,471 billion KRW, and operating profit is estimated to expand by 18.9% year-over-year to 2,460 billion KRW, sustaining an exceptionally high operating profit margin (OPM) of 45.0%.
- Valuation & Profitability Metrics: The estimated Return on Equity (ROE) for 2026 is forecast to rise to 22.5%, showing sequential improvement from 19.4% in 2025. The Price-to-Earnings (PER) multiple is expected to decline significantly to 32.9x (down from 63.8x in 2025), with the Price-to-Book (PBR) ratio tracking at 6.7x and EV/EBITDA at 21.6x.
- Macro Tailwinds & FX Impact: The average KRW/USD exchange rate during the second quarter surged approximately 6.8% to 1,500 KRW (compared to 1,404 KRW in the prior-year period), acting as a massive profitability booster for the company, which derives over 92% of its revenue from overseas exports.
🚀 2. [Section Title: Total Addressable Market (TAM) & Detailed Earnings Forecasts]
- 2Q26 Quarterly Earnings Preview: Second-quarter consolidated revenue is projected at 1,318.9 billion KRW (+30.0% YoY) and operating profit is estimated at 606.1 billion KRW (OPM 46.0%), closely matching the market consensus of 1,324.3 billion KRW in revenue and 592.6 billion KRW in operating profit.
- Labor Dispute Impact Check: A partial 5-day strike initiated by the labor union on May 1 caused minor production friction, pushing roughly 150 billion KRW in expected revenue out of the second quarter. However, this delayed volume is fully scheduled to be recognized within the third quarter, rendering its full-year fundamental impact entirely negligible.
- Second-Half Growth Re-acceleration Pipeline:
- 3Q26 Brief Breathing Room: Revenue expansion may temporarily soften in the third quarter due to the minor production scheduling adjustments stemming from the brief labor union strike.
- 4Q26 Strong Rebound: Growth is set to reactivate sharply in the fourth quarter as the delayed strike volumes roll into billings, further bolstered by new commercial revenue contributions from the US Rockville manufacturing plant and the expanding ramp-up effects of Plant 5.
- Annual Guidance Compliance: The combined second-half momentum ensures the company will seamlessly meet its full-year top-line growth guidance of 15% to 20%.
- Long-Term TAM & Structural Moat: The global antibody therapeutics market—the core operational segment of the company—is projected to expand at a steady compound annual growth rate (CAGR) of 7% through 2029, securing a reliable long-term demand environment for the company’s large-scale contract manufacturing organization (CMO) assets.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics continues to demonstrate its structural resilience, proving that short-term operational frictions are merely brief timing anomalies rather than systemic cracks. The minor revenue deferral caused by May’s brief labor strike has been neatly ring-fenced, with billing transitions poised to lift second-half numbers without disturbing full-year guidance. With the stock trading at a heavily compressed forward multiple compared to historical averages, the current valuation gap looks highly unwarranted given the company’s superior profit margin stability (OPM tracking near 45%) relative to global peers. As the global antibody outsourcing market maintains its 7% structural expansion path through 2029, the combination of a favorable export exchange rate environment, secondary manufacturing revenue via the US Rockville asset, and the massive capacity addition of Plant 5 sets a highly visible floor for a strong share price reversal as second-half uncertainties dissolve.
📢 Disclaimer & Source Information
- Source: This content has been newly structured and written based on publicly disclosed financial facts and numerical data extracted from brokerage research reports.
- Investment Risk Warning: This material is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the individual investor.
- Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
